Under construction – not a live service
Sign in

NCT07920887Not yet recruitingPhase 2

A Study of Bimagrumab in Participants With HFpEF

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Comparing the Efficacy and Safety of Bimagrumab Versus Placebo in Patients With Heart Failure With Preserved Ejection Fraction (ACTIVATE-HFpEF)

Source: ClinicalTrials.gov · Last updated 6 Nov 2026

Next steps

Brief summary (registry, in English)

This study will look at how bimagrumab affects adults who have a type of heart failure called HFpEF (heart failure with preserved ejection fraction), where the heart pumps normally but does not fill with blood as well as it should. Participation in the study will last about 76 weeks.

Status (registry)
Not yet recruiting
Phase (registry)
Phase 2
Study type
Interventional
Enrollment
540 (estimated)
First submitted
29 Oct 2026
Start date
Nov 2026
Primary completion date
Jul 2029
Lead sponsor
Eli Lilly and Company
NCT number
NCT07920887
EU CT number
2026-527983-34-00

What you commit to

  • Study type: Interventional · Phase 2
  • Planned participants: 540
  • From Nov 2026 to the primary completion date, Jul 2029
  • 9 sites in 4 countries
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study design.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Heart failure hospitalization < 4 weeks before screening
  • Myocardial infarction, coronary artery bypass graft surgery, or other major cardiovascular surgery/intervention, stroke or transient ischemic attack in past 12 weeks prior to screening, or unstable angina pectoris in past 4 weeks prior to screening or during screening

Other illness

  • Type 1 diabetes

Lab values

  • Hemoglobin A1c (HbA1c) ≥ 9.5%

Who the study is looking for

  • Have New York Heart Association Class II to III heart failure
  • Have left ventricular ejection fraction (LVEF) ≥ 50%
  • KCCQ-CSS ≤ 80
  • 6MWD must be all of the following:
    • ≥100 and ≤ 450 meters (m) based on average of 2 tests conducted at screening visit, AND
    • ≥ 100 and ≤ 450 m on 1 test at randomization visit, AND
    • < 20% change from average qualifying 6MWD obtained at screening
  • Have documented evidence of at least one of the following:
    • Heart failure event
    • Elevated NT-proBNP (N-terminal pro B-type natriuretic peptide)
    • Left atrium enlargement
    • Elevated filling pressure
  • Stable dose of heart failure medications
  • Body mass index (BMI) ≥ 23 kilograms per meter squared (kg/m²)

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (9)

Sites in registry order. Save your city in your profile to sort them by distance.

SiteCityCountrySite status
Semmelweis Egyetem Varosmajori Sziv- es Ergyogyaszati KlinikaBudapestHungaryUnknown status
Azienda Ospedaliera di Rilievo Nazionale e di Alta Specializzazione Sant' Anna e San Sebastiano di CasertaCasertaItalyUnknown status
A.O. Ordine Mauriziano di TorinoTorinoItalyUnknown status
Krakowski Szpital Specjalistyczny im sw.Jana Pawla IIKrakowPolandUnknown status
Uniwersytecki Szpital Kliniczny im Jana Mikulicza Radeckiego we WroclawiuWroclawPolandUnknown status
4 Wojskowy Szpital Kliniczny z Poliklinika Samodzielny Publiczny ZOZ we WroclawiuWroclawPolandUnknown status
Dharma PA d/b/a Southwest Family Medicine AssociatesDallasUnited StatesUnknown status
Amavita Research Services, LLCNorth Miami BeachUnited StatesUnknown status
Invivocure LLCVan NuysUnited StatesUnknown status

Are you the coordinator? Confirm the details

This page is information, not medical advice. Discuss any trial with your doctor.